Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clovis's Rubraca Leapfrogs Rivals In Ovarian Cancer As ARIEL3 Hits

Executive Summary

Clovis Oncology is forging ahead with a filing for a maintenance indication for its PARP inhibitor Rubraca in a broad ovarian cancer population as new data from ARIEL3 blow the field wide open.

You may also be interested in...



EU CHMP To Decide On New Drugs For Asthma, Diabetes, Hemophilia A, Ovarian Cancer – And Roche’s Ocrevus

Products for a wide range of diseases are expecting a CHMP opinion this week, including orphan drugs for ovarian cancer, eosinophilic esophagitis, and CMV infection, and therapies for asthma, diabetes, and hemophilia A. Roche will be hoping its multiple sclerosis drug Ocrevus can finally clear the CHMP hurdle.

Lynparza Poised For Growth With Broad Ovarian Cancer Approval

AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing, posing a threat to Tesaro's reigning Zejula.

The PARP Combo Race Is On: Clovis And Bristol Partner On Rubraca

Amidst excitement over the potential of PD-1/PARP inhibitor combos in multiple tumor types, Clovis signs a non-exclusive agreement to test Rubraca with Bristol's Opdivo in ovarian, breast and prostate cancer.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel